$30 Billion Tumor Necrosis Factor Inhibiotrs Market &

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
157
$30 Billion Tumor Necrosis Factor Inhibiotrs Market & Clinical Pipeline Outlook 2022

Dublin, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Tumor Necrosis Factor Inhibiotrs Market & Clinical Pipeline Outlook 2022" report to their offering. The anti TNF Drugs (Humira, Remicade & Enbrel) for Rheumatic Disease have combined sales of more than US$ 30 Billion in 2015.

The Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022 report analyzes ongoing clinical and non-clinical trends in the global Tumor Necrosis Factor Inhibitors market. The anti TNF drugs are among the top 10 global block buster drugs and have dominated the global pharmaceutical market landscape for many years.

Over the past decade the pharmaceutical agents directed against TNF-a, infliximab, adalimumab and Etanercept, have been widely and successfully employed for the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, psoriatic arthritis, juvenile idiopathic arthritis and inflammatory bowel disease, and however two novel anti-TNF-a agents such as golimumab and certolimumab pegol, recently entered the market for the treatment of RA, AS, Crohn's disease and psoriasis. The encouragement of the research by the positive results obtained from the use of TNF-a antagonists in terms of efficacy and safety and due to the increasingly collecting the evidence regarding the implication of TNF-a in the pathogenesis of numerous disorders and the anti-TNF-a agents have been considered for the management of diseases other than the ones they were initially approved for. Anti-tumor necrosis factor (TNF) therapy is a valid, effective and increasingly used option in inflammatory bowel disease management. However, the further knowledge and therapeutic indications regarding the drugs are still growing. Anti-TNF therapy may be essential to achieve the recently projected end points and the prevention of bowel damage and prevention of patient's disability. Anti-TNF drugs are also recommended to be more operative in early disease, particularly in early Crohn's disease. Moreover, its efficiency for prevention of postoperative recurrence in Crohn's disease is still debated. Costs and adverse effects, the significance of drug monitoring and the possibility of anti-TNF therapy withdrawal in selected patients are still debated issues. The reviews are expected to describe and discuss the most relevant data about the progress with anti-TNF therapy for the organization of inflammatory bowel disease. Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022 Report Highlight: - Overview of Tumor Necrosis Factor Inhibitors - Approaches Used in Development of Anti-TNF - TNF Inhibitors Market Overview - Tumor Necrosis Factor as an Anti-Cancer Agent - Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication & Phase - Global Tumor Necrosis Factor Inhibitors Pipeline: 151 - Marketed Tumor Necrosis Factor Inhibitors: 25 Key Topics Covered: 1. Introduction to Tumor Necrosis Factor (TNF) 1.1 Basic Structure of the Tumor Necrosis Factor (TNF) Molecule 1.2 Significance of Tumor Necrosis Factor for the Biosynthesis Regulation 1.2.1 Regulation of TNF Biosynthesis at the Transcriptional Level 1.2.2 Regulation the TNF at the Receptor Level 1.3 Tumor Necrosis Factor Receptors 2. Tumor Necrosis Factor Receptor Signaling Pathway 2.1 Tumor Necrosis Factor Receptor1 (TNFR1) Signaling 2.2 Tumor Necrosis Factor Receptor 2 (TNFR 2) Signaling 3. Overview of Tumor Necrosis Factor Inhibitors 3.1 Mechanism of Action of Tumor Necrosis Factor Inhibitors 3.2 Mechanism of Action of Remicade in the Inflammatory Diseases 3.3 Mechanism of Action of the Etanercept 3.4 Mechanism of Action of Humira 4. Approaches Used in Development of Anti-TNF 4.1 Monoclonal Antibody Approach 4.2 Recombinant DNA Technology Approach 5. Function of TNF in Immune Mediated Inflammatory Diseases 5.1 Rheumatoid Arthritis 5.2 Crohn's Disease 5.3 Psoriasis & Psoriatic Arthritis 6. Involvement of TNF & its Receptor in Neurodegenerative Disorders 6.1 Alzheimer's Diseases 6.2 Parkinson's Diseases 6.3 Ischemic Stroke 6.4 Multiple Sclerosis 7. Role of the Tumor Necrosis Factor in the Development of the Cancer 7.1 Introduction 7.2 Tumor Necrosis Factor as Carcinogen 7.3 Tumor Necrosis Factor as an Anti-Cancer Agent 8. TNF Inhibitors Market Overview 8.1 Market of Anti-TNF Blockbuster Drugs 8.1.1 Market of Humira 8.1.2 Market of Enbrel 8.1.3 Market of Remicade 8.2 Global Tumor Necrosis Factor Inhibitors Pipeline Overview 9. Global TNF Inhibitors Market Dynamics 9.1 Accelerative Parameters to the TNF Inhibitor Market 9.2 Challenges to the TNF Inhibitor Market 10. Future Implications of TNF Inhibitor Market 11. Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication & Phase 11.1 Unknown 11.2 Research 11.3 Preclinical 11.4 Clinical 11.5 Phase-I 11.6 Phase-I/II 11.7 Phase-II 11.8 Phase-II/III 11.9 Phase-III 11.10 Preregistration 11.11 Registered 12. Marketed Tumor Necrosis Factor Inhibitors Clinical Insight 12.1 Lumbricus Rubellus Extract (Disolf) 12.2 Certolizumab Pegol (Cimzia, Simziya) 12.3 Apremilast (Otezla) 12.4 Lenalidomide (Ladevina, Revlimid) 12.5 Adalimumab (Humira, Raheara) 12.6 Etanercept (Enbrel) 12.7 Infliximab Biosimilar (Inflectra, Remsima) 12.8 Adalimumab Biosimilar 12.9 Pomalidomide (Imnovid, Pomalyst) 12.10 Belimumab (Benlysta) 12.11 Etanercept Biosimilar (Infinitam) 12.12 Golimumab (Simponi) 12.13 Infliximab Biosimilar (Infimab) 12.14 Infliximab (Remicade) 12.15 Etanercept Biosimilar (Intacept) 12.16 Iguratimod (Careram, Kolbet) 12.17 Thalidomide (Thaled, Thalidomide Celgene, Thalomid) 12.18 Infliximab Biosimilar 12.19 Adalimumab Biosimilar (Exemptia) 12.20 Etanercept Biosimilar (Iran) 12.21 Etanercept Biosimilar (Etacept, Etanar, Yisaipu) 12.22 Iguratimod 12.23 Anti-Tumour Necrosis Factor-Alpha Antibody Oral 12.24 Pentoxifylline (Claudicat, Dospan Pento, Elorgan, Pentoxifilina, Trental) 12.25 Sho-seiryu-to 13. TNF Inhibitors Suspended in Clinical Pipeline 13.1 No Development Reported 13.2 Discontinued 13.3 Suspended 14. Competitive Landscape 14.1 AbbVie 14.2 Ablynx 14.3 Apogenix 14.4 AryoGen Biopharma 14.5 Bionovis 14.6 CASI Pharmaceuticals 14.7 Celltrion 14.8 Celgene Corporation 14.9 Delenex Therapeutics 14.10 Dexa Medica 14.11 EPIRUS Biopharmaceuticals 14.12 Janssen Biotech 14.13 GlaxoSmithKline 14.14 HanAll Biopharma 14.15 Intas Pharmaceuticals 14.16 LEO Pharma 14.17 LG Life Sciences 14.18 MedImmune 14.19 Momenta Pharmaceuticals 14.20 Novartis 14.21 PROBIOMED 14.22 Reliance Life Sciences 14.23 Sandoz 14.24 Samsung Bioepis 14.25 Sanofi-Aventis 14.26 Shanghai CP Guojian Pharmaceutical 14.27 Shanghai Pharmaceuticals 14.28 Simcere Pharmaceutical 14.29 Toyama Chemical 14.30 Tsumura 14.31 UCB 14.32 Zydus Cadila For more information about this report visit http://www.researchandmarkets.com/research/39...r_necrosis

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Oncology Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 81

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 123

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 68

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 147

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 94

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 71

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Nokia and Microscan Collaborate for Enhanced Optical Networks

Updated Category News Views 262

Nokia and Microscan Join Forces for Optical Network Enhancement Nokia and Microscan have teamed up to create a high-capacity metro and regional optical network in Western India, marking a significant advancement in regional connectivity. This collaboration targets boosting bandwidth and improving overall network reliability for a variety of customers, including...

Continue Reading
Southland Secures $160 Million Credit Facility for Expansion

Updated Category News Views 80

Southland Holdings Enters $160 Million Credit Facility Southland Holdings, Inc. (NYSE American: SLND and SLND WS), recognized as a leader in specialized infrastructure construction services, has successfully closed a new senior secured credit facility valued at $160 million. This new financial arrangement includes an initial draw term loan of $140 million and a delayed...

Continue Reading
Discover the Benefits of the New ezPaycheck Payroll Network

Updated Category News Views 199

Introducing the ezPaycheck Network Version for Businesses The ezPaycheck payroll software has released its 2025 network version, aimed at enhancing productivity for growing companies and remote workers. This update brings numerous advantages, ensuring businesses can efficiently manage payroll, regardless of where their team operates. Key Features of the ezPaycheck Network...

Continue Reading
Nokian Tyres' Profits Surge Amidst Flat Market

Updated Category News Views 60

Profit Spike Fueled by Strategic Moves Amid an insipid global tire market shaking with economic jitters, Nokia’s own Nokian Tyres somehow pulled a rabbit out of a hat. If this isn’t proof that strategy and perseverance pay off, what else is? This Finnish giant just rolled in with earnings that shout, 'We’re doing something right!' Let’s break down how they fared...

Continue Reading
CGI Enhances Veteran Support with MyWWP Connection Portal

Updated Category News Views 139

CGI Partners with Wounded Warrior Project to Help Veterans CGI (TSX: GIB.A) (NYSE: GIB), a leader in IT and business consulting, is proud to announce its collaboration with the Wounded Warrior Project to develop MyWWP, a robust digital portal dedicated to supporting wounded veterans and their families. This enhanced online platform is designed to connect users with...

Continue Reading